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Retinitis pigmentosa (RP) is an inherited retinal disease that leads to degeneration
of the retina through loss of rod and cone photoreceptor cells and subsequent loss of vision.
RP affects approximately 1.5 million people world-wide. Mutations causing autosomal
dominant retinitis pigmentosa (adRP) have been identified in 23 different genes. However,
these mutations only account for approximately 70% of known adRP cases in Caucasians of
Western-European origin and for an even smaller percentage of cases in other ethnicities.
My research aims to increase the number of known genes associated with adRP by using an
array of advanced genetic techniques to search for the disease-causing gene and mutation in
a large African American family that has been clinically diagnosed with adRP. Sanger
sequencing, targeted-capture next-generation sequencing (NGS), and multiplex ligationdependent probe amplification (MLPA) were used to evaluate and eliminate the known
adRP genes as the genetic cause of disease in this family. Whole-genome linkage mapping
followed by fine-point haplotype analysis mapped the disease locus to a 7.7 mega-base
region on chromosome 19q. Five candidate genes from within this disease locus were
chosen based on their biological relevance to RP and analyzed for possible disease-causing
mutations. Whole-exome sequencing and whole-genome sequencing were used to identify
63 rare variants located throughout the disease locus that segregate with disease in this
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family. Additional genetic and bioinformatic analyses were completed to evaluate these
variants’ potential to be disease-causing.
Despite being unable to single-out the disease-causing mutation from among the
variants found to segregate with disease in this family, the wealth of data produced in this
study will provide necessary genetic information that will continue to aid others in the
search for this family’s disease-causing gene. Once this novel adRP gene is identified, it
will provide valuable insights that can be used in the diagnosis and prognosis of RP in this
family and in other RP patients identified to have mutations in the same underlying gene.
Of more importance, identification of the remaining disease-causing genes for adRP is
necessary for the continued success that has been seen in the development of treatments and
therapies for RP patients.
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Chapter 1: Introduction
Our sense of sight is considered by many to be the most valuable and most
frequently used of our five senses. Unfortunately, patients diagnosed with retinitis
pigmentosa (RP) lose their vision, forcing them to adapt to this life-altering change as best
as they are able. The research contained in this study aims to help continue the success seen
in identifying the genetic causes of RP and ultimately provide clinicians and scientists with
the information they need to help diagnose and, one day, treat RP patients.
Retinitis Pigmentosa Background
RP is an inherited retinal degeneration that results in progressive loss of the rod
photoreceptor cells. [1 - 3] Photoreceptors are specialized sensory cells located in the outer
nuclear layer of the retina that are responsible for absorption of light and turning light into
signals that can be sent to the brain. [1, 3 - 4] There are two types of photoreceptors, rods
and cones. [4] Rods are concentrated around the periphery of the retina and are responsible
for monochromatic vision at night and in dim lighting. [1] Cones are concentrated in the
center of the retina and are responsible for color discrimination and high acuity vision. [1]
RP affects approximately 1 in 4,000 individuals and causes patients to progressively
lose their vision. [1 - 2] As RP is a rod photoreceptor dominated disease, patients’ vision
loss typically starts with loss of their night vision. [1 - 3] Progression of the disease will
then lead to constriction of their visual fields, resulting in ‘tunnel vision’. [1 - 3] Since
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degeneration of rod photoreceptor cells often results in secondary degeneration of cone
photoreceptor cells, many patients will become completely blind as vision loss progresses
into their central retina. [1 - 3] Additional clinical symptoms include the presence of
intraretinal pigmentation (typically referred to as ‘bone spicule’ pigmentation), retinal blood
vessel attenuation, and waxy optic disc pallor seen in the fundus photographs of a patient’s
retina (Figure 1). [1 - 3] Electroretinograms (ERGs) of RP patients, which measure the
electronic response of the retina to flashes of light, are seen as abnormal and diminished and
often progress to completely nonrecordable. [1 - 2]
RP is an extremely heterogeneous disease that displays multiple examples of clinical
heterogeneity. The age of onset, degree of severity, and level of cone involvement can vary
from patient to patient, even within the same family. [1 - 3] Some RP genes, such as
PRPF31 and RP1, have exhibited cases of incomplete penetrance, and different mutations in
the same gene may cause differing RP symptoms. [2, 5] There are also syndromic forms of
RP in which there are additional non-ocular symptoms associated with the disease. For
example, Usher syndrome, in which RP is associated with hearing loss, is the most common
syndromic form of RP. [1 - 2] Another major form of syndromic RP is Bardet Biedl
syndrome, in which obesity, developmental delay, polydactyly, hypogenitalism, and renal
disease are associated with RP to varying degrees. [1 - 2]
RP also exhibits high levels of genetic heterogeneity. RP has multiple forms of
inheritance, including autosomal dominant, autosomal recessive, X-linked, and rare cases of
digenic and mitochondrial inheritance. [1 - 2] The autosomal dominant form accounts for
approximately 30% of known non-syndromic RP cases in the US, while the autosomal
recessive form accounts for approximately 20% of known cases. [6] X-linked forms
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Figure 1. Fundus photographs of a normal (left) and RP (right) retina. The
clinical features of RP, ‘bone spicule’ pigmentary deposits, retinal blood vessel
attenuation, and waxy optic disc pallor, can be seen in the retina affected by RP.
[Figure reprinted by permission from Macmillan Publishers Ltd: The EMBO
Journal (Farrar, G.J., Kenna, P.F., Humphries, P. On the genetics of retinitis
pigmentosa and on mutation-independent approaches to therapeutic intervention.
EMBO J. 21, 857-864 (2002) ), copyright 2002.]
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account for an additional 15% of known non-syndromic RP cases, and 5% of these
nonsyndromic cases are early-onset forms of RP that are usually diagnosed as Lebers
congenital amaurosis (LCA). [6] Approximately 30% of remaining nonsyndromic RP cases
are isolated or simplex cases. [6] The majority of these isolated cases will likely be
diagnosed with recessive RP mutations, but dominant-acting mutations and X-linked
mutations are also included among these individuals. [6] To date, 63 genes have been
identified to cause non-syndromic RP. Twenty-three genes have been identified to cause
autosomal dominant RP (adRP), 42 genes to cause autosomal recessive RP (arRP), and three
genes to cause X-linked RP (XLRP). [5, 7] These numbers add up to more than 63 because
many RP genes can cause more than one form of RP. Approximately 3,100 different
mutations have been reported in these genes. [5] These genes encode proteins involved in a
wide range of functions that include phototransduction, pre-mRNA splicing, retinal
development, and photoreceptor outer-segment structure (Figure 2). [1, 4, 7]
The family examined in this study was clinically diagnosed with adRP after the
proband received a thorough visual function exam at the Retina Foundation of the Southwest
in Dallas, Texas. Therefore, the remainder of this dissertation will focus on the nonsyndromic, autosomal dominant form of RP.
Previous Identification of adRP Genes
In 1990, linkage analysis and candidate gene sequencing were used to identify the
first adRP gene, rhodopsin (RHO). [9] Since then, each of the remaining adRP genes (Table
1) has also been identified with the traditional genetic methods of linkage analysis followed
by candidate gene sequencing. [10 - 13] RPE65, one of the 23 known adRP genes,
represents the first successful use of next-generation sequencing (NGS) technologies in the
4

Figure 2. Pie chart of the genes involved in photoreceptor degeneration grouped
into functional categories. ECM, extracellular matrix; VRD, vitreoretinal
degeneration. [Figure reprinted by permission from Macmillan Publishers Ltd:
Nature Reviews Genetics (Wright, A.F., Chakarova, C.F., Abd El-Aziz, M.M.,
Bhattacharya, S.S. Photoreceptor degeneration: genetic and mechanistic
dissection of a complex trait. Nature Rev. Genet. 11, 273-284 (2010) ), copyright
2010.]
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Table 1. Autosomal dominant retinitis pigmentosa genes
Genea
BEST1
CA4

Protein Product
Chromosome
Bestrophin 1
11
Carbonic anhydrase 4
17
Cone-rod otx-like photoreceptor homeobox
CRX
19
transcription factor
Retinal fascin homolog 2, actin bundling
FSCN2
17
protein
GUCA1B
Guanylate cyclase activating protein 1B
6
IMPDH1
Inosine monophosphate dehydrogenase 1
7
KLHL7
Kelch-like 7 protein
7
NR2E3
Nuclear receptor subfamily 2 group E3
15
NRL
Neural retina lucine zipper
14
Human homolog of yeast pre-mRNA splicing
PRPF3
1
factor 3
Human homolog of yeast pre-mRNA splicing
PRPF6
20
factor 6
Human homolog of yeast pre-mRNA splicing
PRPF8
17
factor C8
Human homolog of yeast pre-mRNA splicing
PRPF31
19
factor 31
PRPH2
Peripherin 2
6
RDH12
Retinol dehydrogenase 12
14
RHO
Rhodopsin
3
ROM1
Retinal outer segment membrane protein 1
11
RP1
RP1 protein
8
RP9 protein or PIM1-kinase associated
RP9
7
protein 1
Retinal pigment epithelium-specific 65 kD
RPE65
1
protein
SEMA4A
Semaphorin 4A
1
SNRNP200 Small nuclear ribonucleoprotein 200kDa (U5)
2
Topoisomerase I binding arginine/serine rich
TOPORS
9
protein
a
Number of known adRP genes is based on the RetNet database,
http://www.sph.uth.tmc.edu/retnet/ , accessed October 2013 [7]
b

Mutationsb
238
7

Number of mutations in known adRP genes is based on the Human Gene Mutation
Database, http://www.hgmd.cf.ac.uk/ , accessed November 2013 [8]
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54
1
3
15
3
50
14
3
2
21
66
123
67
162
11
68
2
136
3
10
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identification of a dominant RP gene. RPE65 had previously been identified to cause arRP
and Leber congenital amaurosis (LCA). [14] RPE65’s dominant acting mutation was
identified by whole-exome sequencing and the simultaneous use of linkage analysis and
candidate gene sequencing. [14]
Despite the success seen in identifying the genetic causes of adRP over the past two
decades, the 23 genes known to cause adRP only account for 65-70% of known cases of
adRP. [5, 14 - 15] While linkage analysis and candidate gene sequencing has contributed to
the identification of all 23 adRP genes, it is a labor- and resource-intensive process. These
traditional genetic approaches have also had difficulty overcoming some aspects of rare
genetic diseases such as high levels of genetic heterogeneity, incomplete penetrance, and the
availability of only a small number of patients to study. [16] Therefore, many hope that
NGS is the powerful and unbiased technology that will help us solve the remaining
genetically unknown adRP cases.
Next-Generation Sequencing
The advent of NGS technologies and the continual improvement of these
technologies has exponentially reduced the cost and increased the speed of sequencing,
thereby aiding geneticists in their search for the genetic causes of Mendelian diseases. [16 18] The challenge that still remains for the use of NGS strategies in the search for novel
disease genes (especially in dominant diseases) is how to identify disease-causing mutations
from among the wealth of genetic data produced by whole-exome and whole-genome
sequencing. [16 - 18] The large amount of variant data to search through, an inability to
completely understand the effects of non-coding variation, the presence of non-pathogenic
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polymorphisms, and sequencing errors adds complications to an already difficult process.
[17 - 18]
While NGS has led to the identification of one adRP gene, RPE65, it has been most
successful in the identification of autosomal recessive disease-causing genes, aided by the
ability to use homozygosity mapping in the identification process (5, 14, 19 - 20).
Additionally, most successes in identification of the disease-causing gene in autosomal
dominant disorders have been preceded by linkage analysis of a pedigree where
identification of the disease locus helped to focus the search. [14, 16]
My Research
The goal of my research is to identify the disease-causing gene and mutation in a
large African American family that has been clinically diagnosed with adRP. A systematic
use of multiple genetic technologies was employed in the search for this family’s diseasecausing gene (Figure 3). Following enrollment and clinical characterization of the family
analyzed in this study (Chapter 2), all previously known causes of adRP were evaluated and
eliminated as their genetic cause of disease (Chapter 3). Furthering the pursuit of their
genetic cause of disease, whole-genome linkage analysis was performed to identify the
disease locus (Chapter 4). Five candidate genes based on biological relevance and previous
adRP information found within this region were sequenced with the end goal of identifying
potential disease-causing mutations (Chapter 5). After analysis of these candidate genes
failed to elucidate the disease-causing mutation, NGS technologies were used to continue
the search and identify all genetic variation present within the chromosome 19q disease
locus (Chapter 6). Additional genetic and bioinformatic analyses were completed to assess
the pathogenic potential of all variants segregating with disease in the family (Chapter 7).
8

Identifying the genetic cause of this African American family’s adRP will provide
clinicians and scientists with valuable information, which can be used in a more thorough
diagnosis and prognosis of their disease. This information will also be used to benefit other
RP patients with mutations in the same gene. Finally, identification of the disease-causing
gene and subsequent identification of the biological pathway involved in the disease will aid
in the development of treatments for RP patients with mutations in this gene.
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Figure 3. Flow chart of the analytical steps used in this study. The steps are
arranged in a circle to illustrate the cyclic nature of this research process; each
new piece of information involves a re-evaluation of what we know at all of the
previous steps and feeds in to how we approach the following steps.
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Chapter 2: Family Acquisition and Clinical Characterization
Introduction
One limiting factor for studying rare genetic diseases is availability of genetic and
phenotypic information from patients with the disease. RP’s vast amount of clinical and
genetic heterogeneity can translate into an equally large amount of possible genetic causes
of disease. Thorough clinical examinations that note the presence of additional non-ocular
symptoms, degree of severity, level of rod versus cone involvement, and possible cases of
incomplete penetrance will help determine which of the known RP genes is the cause of
disease and will help guide the search for a novel RP gene. The ultimate goal of my
research is to identify valuable genetic information that will aide in the diagnosis, prognosis,
and eventual treatment of patients with RP. To obtain this goal, RP patients willing to
participate in these genetic research studies must be identified, enrolled, and clinically
characterized.
A large African American family, referred to as RFS132, was clinically diagnosed
with adRP and enrolled in this study. Several members of the family were given
comprehensive visual function exams, and DNA samples were obtained from each of the 28
participating family member for use in all proceeding genetic analyses.
Methods
Enrollment
After the proband of the RFS132 family received a clinical diagnosis of adRP for his
declining vision, several RFS132 family members were enrolled in my study at the Retina
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Foundation of the Southwest in Dallas, Texas. Additional family members were enrolled in
the study when a few members of the Daiger Laboratory made a trip to the family’s home.
Informed consent was obtained from each participating individual or from parents/guardians
for individuals under age 18. Each individual was also given a unique laboratory identifier
that was used on all DNA samples and in construction of the family’s pedigree. This study
was performed in accordance with the tenets of the Declaration of Helsinki and was
approved by the Committee for the Protection of Human Subjects of the University of Texas
Health Science Center at Houston.
Visual Function Exams
Several members of the RFS132 family received comprehensive visual function
examinations at the Retina Foundation by Dr. David Birch and the Retina Foundation’s
genetic counselor, Dr. Dianna Wheaton. These visual function exams included
measurement of best-corrected visual acuity (BCA), full-field International Society for
Clinical Electrophysiology of Vision (ISCEV) standard dark-adapted electroretinograms
(ffERG), dark-adapted visual thresholds, and Humphrey visual fields (30-2; Spot size III
protocol). [21] Fundus photographs and optical coherence tomography imaging (OCT) of
the patients’ retinas were also part of the examination.
DNA Extraction
Blood or saliva samples were obtained from each study participant in the RFS132
family. DNA was extracted from whole blood using either the QIAamp DNA Blood kit or
Gentra Puregene blood kit (Qiagen, Hilden, Germany). DNA was extracted from saliva
using the Oragene Saliva Collection Kit (DNA Genotek, Ontario, Canada).
12

Results
To date, 28 members of the RFS132 family have been enrolled and appropriately
consented for participation in this research. A pedigree for this family was built from
information collected from the family at the time of enrollment (Figure 4). The twenty-eight
individuals make up three generations of the RFS132 family and include 13 affected family
members, 12 unaffected, at-risk family members, and three unaffected spouses. DNA
samples, in the form of blood or saliva, were collected from each of these individuals for use
in this study.
Several members of this family (denoted with a “*” in Figure 4) were given
comprehensive visual function exams. The proband, RFS132-5463, has been examined
three times since 1998. His most recent examination was in 2011 at age 56. At his last
examination, RFS132-5463 had a visual acuity of 20/80 OD and 20/40 OS. ISCEV-standard
ERG rod responses to single flashes of blue light were reduced in amplitude by 18%. Cone
responses to 30-Hz flicker were reduced in amplitude by 14% and were significantly
delayed in b-wave implicit time. His dark-adapted visual thresholds were elevated 1.5 log
units, and his central visual fields, measured by Humphrey perimetry, showed a large central
scotoma covering most of the central visual field. These findings are consistent with a
diagnosis of RP.
The remaining affected individuals that received exams, while seen at different ages,
had varying degrees of severity in their symptoms. For example, RFS132-7473 was seen in
2011 at age 35, which is 21 years younger than RFS132-5463 at his last exam. The results
of his visual function exam displayed a higher degree of severity in the progression of his
vision loss than for RFS132-5463. At his 2011 examination, RFS132-7473 had a measured
13

Figure 4. Pedigree of the RFS132 family. Blackened symbols indicate family
members that have been diagnosed with RP. “?” indicates a family member with
an unknown disease status. “*” denotes the family members that received
comprehensive visual function exams.
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visual acuity of count fingers OD and 20/400 OS. ISCEV-standard ERG rod responses to
single flashes of blue light were non-detectable. Cone responses to 30-Hz flicker were
reduced in amplitude by 94% and significantly delayed in b-wave implicit time. His darkadapted visual thresholds were elevated 3.7 log units. Like RFS132-5463 and RFS1327473, each of the remaining affected individuals who received exams also showed ERG
results with diminished or non-recordable rod responses and diminished cone responses.
Each individual also exhibited elevated dark-adapted visual thresholds.
Discussion
Studies such as this one would not be possible without the cooperation and willing
participation of RP patients. The successful enrollment of 28 individuals spread across three
generations of the RFS132 family provides the background for this study. DNA samples
collected from each individual will be used to complete all the proceeding genetic analyses.
RFS132’s visual function examinations provide clinical information that can be used
to help guide the search for their genetic cause of disease. Those examined displayed
varying degrees of severity in their symptoms, which is typical of RP. Each family member
that received a comprehensive exam displayed poor visual acuity and elevated dark-adapted
thresholds. The family’s ERG responses showed significant loss of the cone photoreceptors
in addition to the loss of their rod photoreceptors. Examination of the family’s pedigree
showed no detectable instances of non-penetrance.
Working with the family is an important and ongoing process. Since RP has varying
degrees of severity and ages on onset, known cases of incomplete penetrance, and related
syndromic forms of disease, getting patients in for updated examinations is imperative to
obtaining an accurate clinical and molecular diagnosis. Churchill, et al. 2013 and Wang, et
15

al. 2013 are examples of studies where identification of the genetic cause of disease resulted
in the need to reassess a family’s clinical diagnosis. [15, 22] Additionally, several members
of RFS132, such as RFS132-7473, have children that can be enrolled in this study. Each
child of an affected family member has a 50% chance of inheriting the RP gene. Those
children carrying the affected haplotype might also have novel recombinations that could
help narrow the search for the disease-causing gene. Therefore, our clinical collaborators at
the Retina Foundation and I will continue to encourage members of the RFS132 family to
obtain updated visual function exams and will continue working towards enrolling
additional family members in this study throughout the duration of the study.

16

Chapter 3: Elimination of Known Causes of Disease
Introduction
Scientists have made great progress over the past two decades in identifying the
genetic causes of adRP. The 23 known adRP genes allow for the molecular diagnosis of 6570% of known cases of adRP. [5, 7] The first step in identifying RFS132’s disease-causing
gene is to search for possible disease-causing mutations among the known adRP genes.
While Sanger sequencing has long been considered the gold-standard of sequencing
technologies, NGS strategies have seen an enormous growth in popularity over recent years.
[16 - 18] Whole-exome and whole-genome sequencing strategies have made an impact in
identification of novel disease-causing genes. [16 - 17] A third NGS strategy, targetedcapture NGS, provides scientists with an efficient and powerful option to screen patients for
all known causes of their disease. [5, 16] Several recent studies have reported the successful
use of targeted capture NGS analysis for molecular diagnosis of RP patients. [22 - 23] In
addition to the impressive molecular diagnosis rates, these NGS strategies allow for
expansion of analysis beyond just the known RP genes by adding additional candidate
retinal disease genes to the targeted capture step. [22 - 24] In several instances, this has
resulted in the identification of genes that can cause multiple forms of RP or genes that can
cause multiple types of inherited retinal dystrophies. [22 - 24]
Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and
targeted-capture NGS were used to search for potential disease-causing mutations in the
known adRP genes in the RFS132 family. Sanger sequencing was used to sequence the
exons and exon/intron junctions of the known adRP genes. MLPA was used to screen for
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copy number variants (CNVs) and genomic rearrangements that might be missed by
conventional sequencing techniques in a subset of the known adRP genes. NGS targeted
capture was used to analyze the exons and splice junctions of 163 known retinal disease
genes.
Methods
Sanger Sequencing
A minimum of one affected individual from RFS132 was selected and screened for
mutations in the known adRP genes, including the complete coding regions of CRX,
GUCA1B, IMPDH1, PRPF6, PRPF31, RDS, RDH12, RHO, RP1, RPE65, SEMA4A,
SNRNP200, and TOPORS and mutational hotspots of PRPF3 and PRPF8. AmpliTaq
Gold® 360 Master Mix (Life Technologies, Grand Island, NY) and M13-tailed primers
designed in Primer3 were used to amplify genomic DNA in a 12.5 µL reaction volume for
35 cycles. [25 - 26] The resulting PCR product was treated with ExoSAP-IT® (Affymetrix,
Santa Clara, CA). Purified PCR product was sequenced bidirectionally with M13 primers
and BigDye v1.1 (Life Technologies). Sequence reactions were purified with BigDye
Xterminator® purification kit and run on a 3500 Genetic Analyzer (Life Technologies).
Sequence analysis was then performed with SeqScape® v3.0 or Sequencing Analysis (Life
Technologies).
MLPA
MLPA was completed as previously described using probe pairs designed to span the
coding regions of CRX, FSCN2, PRPF31, RDS, RHO, RPE65, and TOPORS and mutational
hotspots of PRPF3 and RP1, reagents in either one of two kits (MLPA P115 Retina or EK1
18

kit; MRC-Holland, Amsterdam, The Netherlands), and the manufacturer’s DNA detectionquantification protocol. [27 - 28] Probes were designed based on the recommendations of
MRC-Holland using Raw-Probe software (MRC-Holland).
Probe cocktails were hybridized overnight with 25-50 ng of genomic DNA.
Hybridized probes were ligated and then PCR amplified following the manufacturer’s
protocol. PCR product was diluted in deionized formamide (Life Technologies) containing
GeneScan-500 LIZ size standards (Life Technologies) and run on a 3100-Avant Genetic
Analyzer (Life Technologies). Initial analysis of PCR products was completed with
GeneMapper® software v3.7 (Life Technologies). Tables of peak heights and peak areas
were exported from GeneMapper® to a spreadsheet in Excel (Microsoft, Redmond, WA.)
Dosage quotients (DQs) were calculated for each probe as detailed by Stern et al. 2004. [29]
A DQ of 1.0 would indicate the presence of two alleles, and a DQ of 0.5 or 1.5 would
indicate the possible presence of either a deletion or duplication of the target sequence,
respectively. [29]
Targeted Capture NGS Sequencing
One affected individual from the RFS132 family was screened for mutations in 163
retinal disease genes (Appendix A) with targeted capture NGS in collaboration with Dr. Rui
Chen at the Human Genome Sequencing Center, Baylor College of Medicine, Houston,
Texas. [22] Illumina libraries were prepared according to previously described protocols.
(Illumina Inc, San Diego, CA) [22, 30] NimbleGen SeqCap EZ Hybridization and Wash
Kits and manufacturer’s protocol were used for the retinal gene capture. (Roch Nimblegen
Inc, Madison, WI) DNA libraries were quantified and sequenced, after capture of the
targeted retinal genes, on an Illumina HiSeq 2000 following the manufacturer’s protocols.
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The 100 base-pair (bp) paired end reads produced by sequencing were analyzed according to
previously described methods. (22, 30)
Results
At least one affected member of the RFS132 family was screened for mutations in
the known adRP genes, including the complete coding regions of CRX, GUCA1B, IMPDH1,
PRPF6, PRPF31, RDS, RDH12, RHO, RP1, RPE65, SEMA4A, SNRNP200, and TOPORS
and mutational hotspots of PRPF3 and PRPF8, by di-deoxy Sanger sequencing.
Sequencing of these genes included the known coding exons and 15 bps of intronic
sequence at exon/intron junctions. Variations from the reference sequence were further
analyzed for the possibility of causing disease. A variant’s presence among unaffected,
ethnically matched controls, identification as a known polymorphism in online genetic
databases such as the 1000 Genomes Browser (http://browser.1000genomes.org/index.html)
and the NHLBI Exome Sequencing Project Exome Variant Server (NHLBI GO Exome
Sequencing Project (ESP): https://esp.gs.washington.edu/drupal/), and/or failure to cosegregate with disease among additional family members eliminated the variants likelihood
to cause disease. [31 - 32] Sanger sequencing analysis failed to reveal any disease-causing
mutations among the known adRP genes in this family.
One affected family member was also screened for CNVs and genomic
rearrangements in a subset of the known adRP genes, including the coding regions of CRX,
FSCN2, PRPF31, RDS, RHO, RPE65, and TOPORS and mutational hotspots of PRPF3 and
RP1 using MLPA. The probes used for MLPA were designed to overlap with the PCR
primers used in Sanger sequencing analysis, so any failure to amplify would also be
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detected. MLPA analysis did not reveal any CNVs or genomic rearrangements among the
genes analyzed.
The retinal disease gene capture panel completed in collaboration with Dr. Rui Chen
of Baylor College of Medicine’s Human Genome Sequencing Center was used to screen an
affected member of RFS132 for mutations in 163 retinal disease genes, including 48 RP
genes and 115 additional retinal disease genes. The capture panel included 2,560 exons and
splice junction, totaling 649,804 bps. The mean read depth coverage was 77X with 92% of
the targeted region reaching at least 10X coverage. Only 49 of the 2,560 exons had a read
depth of less than five and, thus, were not efficiently covered. The design of the capture
panel also failed to include 21 exons of EYS and 51 exons of USH2A. The sequencing data
was analyzed with an automatic variant calling, filtering, and annotation pipeline that has
been previously described. [22, 30] Common polymorphisms were filtered out from initial
variant calls by comparison to genetic databases such as the 1000 Genomes Browser
(http://browser.1000genomes.org/index.html), dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP/), and the NHLBI Exome Sequencing Project
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP):
https://esp.gs.washington.edu/drupal/ ) and an internal control database of 997 exomes. [31 33] The remaining rare variants were annotated and evaluated for possible pathogenicity by
comparison to the Human Gene Mutation Database (HGMD) and in silico analysis using
dbNSFP. [8, 34] Targeted capture NGS failed to reveal any disease-causing mutations
among these 163 retinal disease genes in this family.

21

Discussion
Sanger sequencing was used to sequence the coding regions of the known adRP
genes. Large insertions, deletions, or genomic rearrangements were screened for in a subset
of these adRP genes using MLPA. Targeted-capture NGS was used to sequence the exons
of 48 RP genes and 115 retinal disease genes. Variations identified within any of these
genes were further evaluated for their potential to be disease-causing. Each method failed to
identify a disease-causing mutation in any of the genes analyzed.
While these sequencing methods did not identify any disease-causing mutations
within the coding regions or splice junctions of the genes analyzed, it does not fully
eliminate intronic or regulatory variants located in or around these genes as potential causes
of disease. However, the following chapters will discuss additional analyses that further
confirm the elimination of the known adRP genes as the cause of disease in this family. The
linkage analysis discussed in chapter 4 eliminates all but CRX as a possible cause of disease.
Chapter 5 covers extending the Sanger sequencing analysis of CRX beyond the exons and
exon/intron junctions. Chapters 7 and 8 examine the identification and elimination of all
NGS variants located in known adRP genes, including the intronic and regulatory regions.
The combination of results from all these analyses caused the need to expand the search for
RFS132’s genetic cause of disease to novel adRP genes.
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Chapter 4: Linkage Mapping of Disease Locus
Introduction
The human genome is comprised of over three billion base-pairs of DNA organized
into approximately 21,000 protein-coding genes. Therefore, the opportunity to narrow the
search for a family’s disease-causing gene to a specific chromosomal region of the genome
will greatly increase researchers’ success for molecular diagnosis. In fact, every known
adRP gene has first been localized by linkage mapping. [10 - 13] After eliminating the
known adRP genes as the disease-causing gene in RFS132, the next step in identifying this
family’s genetic cause of disease was to map the disease-causing gene to a specific
chromosomal region.
Whole-genome linkage analysis was performed on a subset of the RFS132 family
using genotyping data from an Affymetrix 6.0 SNP array to identify potential chromosomal
regions segregating with disease. Short tandem repeat (STR) markers were then genotyped
in the whole family and used to generate haplotypes of each candidate chromosomal region
identified by whole-genome linkage analysis. These haplotypes were then used to confirm
and refine the identified regions. Recombinant individuals in the RFS132 pedigree were
used to redefine the boundaries of the disease locus. Additionally, CNV probes on the
Affymetrix 6.0 SNP array were used to search for copy number variations in a subset of the
RFS132 family
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Methods
SNP Genotyping
DNAs from 17 members of RFS132 (11 affected and 6 unaffected individuals) were
available for whole-genome linkage analysis. Genotyping was completed using the
Affymetrix Genome-Wide Human SNP Array 6.0 by the John P. Hussman Insititute for
Human Genomics, Center for Genome Technology in Miami, Florida in collaboration with
Dr. Susan Blanton. An ND-8000 spectrophotometer (Thermo Fischer Scientific, Waltham,
MA) and agarose gel electrophoresis was used to evaluate the quantity and quality of DNA
respectively. Qualifying DNA was digested with NspI and StyI restriction enzymes (New
England Biolabs, Ipswich, MA, USA) and ligated to adapters. The DNA was then amplified
using adapter-specific primers. After purification, PCR products were fragmented, labeled,
and loaded on the SNP arrays. Hybridization was completed overnight in a GeneChip
Hybridization Oven (Affymetrix). Arrays were washed and stained with streptavidin
phycoerythrin (SAPE) on the Fluidics Station 450 (Affymetrix). Arrays were scanned on a
GeneChip Scanner 3000 7G (Affymetrix).
Whole-Genome Linkage Analysis
Genotyping Console software (Affymetrix) was used to make SNP genotype calls
and perform CNV analysis on raw Affymetrix Genome-Wide Human SNP 6.0 array data.
PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) was used for quality control and
assessment. [35] A subset of the genotyped SNPs was chosen for linkage analysis based on
heterozygosity and inter-SNP distance. The chosen SNPs were at least 0.2 cM apart and had
an average heterozygosity of 0.5. YRI (Yoruba in Ibadan, Nigeria) dataset allele
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frequencies were used for this family’s calculations. [36] Multipoint linkage analysis was
performed using Merlin v1.1.2 (http://www.sph.umich.edu/csg/abecasis/Merlin/download/)
and a dominant model with 90% penetrance in heterozygotes and a disease allele frequency
of 0.0001. [37 - 38]
STR Genotyping
Polymorphic STR markers were selected for use from the UCSC Genome Browser
(http://genome.ucsc.edu/) and were purchased from Life Technologies. AmpliTaq Gold®
360 Master Mix (Life Technologies) and fluorescently labeled primers (Life Technologies)
were used to amplify patient DNA in a 7.5 µL reaction volume for 30 cycles. Resulting
PCR products were run on a 3500 Genetic Analyzer (Life Technologies).
Manual Haplotype Analysis
Raw STR genotype data were analyzed using GeneMapper® v5.0 (Life
Technologies). Individual haplotypes of each family member were generated by hand using
the genotyped STR data and assembled onto the RFS132 pedigree.
Results
Affymetrix 6.0 genotypes were used to complete whole-genome, multipoint linkage
analysis and CNV analysis on a portion of the RFS132 family. CNV analysis of the data
generated by the 946,000 copy number probes on the Affymetrix 6.0 SNP array in
Genotyping Console software did not identify any copy number variants in RFS132.
However, whole-genome linkage analysis using a subset of the SNP genotypes identified
three chromosomal regions with a positive LOD score. These linkage regions were located
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on chromosomes 9, 18, and 19 with maximum multipoint LOD scores of 2.5, 3.5, and 3.8
respectively (Figure 5). The chromosome 9 linkage region was approximately 3.7 megabases (Mb) in size and was flanked by rs1013217 and rs7852051. The chromosome 18
linkage region was approximately 5.3 Mb in size and was flanked by rs2879526 and
rs4940674. The final linkage region, on chromosome 19, was approximately 7.7 Mb in size
and was flanked by rs2599472 and rs10405562. The LOD scores on each of these specific
chromosomal regions suggested they could be linked to the family’s disease.
Fine-point haplotyping using STR markers flanking and spanning the three
chromosomal regions identified by whole genome linkage analysis was completed on the
original 17 samples plus at least 8 additional samples from RFS132 to confirm and refine the
number of potential disease loci. Nine STR markers (Table 2) were run on chromosome 9,
and haplotypes were generated to search for one tracking with disease (Figure 6). RFS1327827 and RFS132-5722 lacked the haplotype seen in the remaining affected family
members. Ten STR markers (Table 2) were run on chromosome 18, and haplotypes were
generated to search for one tracking with disease on this chromosome (Figure 7). Once
again, RFS132-7827 and RFS132-5722 lacked the haplotype seen in the remaining affected
family members. Fifteen STR markers (Table 2; Appendix B) were run on chromosome 19,
and haplotypes were generated to search for one tracking with disease (Figure 8). One
haplotype was found in each affected member of the RFS132 family, segregating
appropriately with disease. The affected haplotype was also seen in five unaffected, at-risk
family members. Further examination of the affected haplotype revealed multiple
recombinant individuals. A recombination between D19S420 and D19S900 in RFS1325721 redefined the centromeric boundary of the linkage region, and a recombination
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Chromosome 9

Chromosome 18

Chromosome 19

Figure 5. Whole-genome linkage analysis results for chromosomes 9, 18, and 19
(respectively).
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Table 2. STR markers. A list of the genetic markers used in
the fine point haplotype analysis of the three linkage regions
identified by whole-genome linkage analysis.
Chromosome 9
D9S169
D9S52
D9S911
D9S1878
D9S1817
D9S1805
D9S1859
D9S1874
D9S2148

Chromosome 18
D18S1156
D18S487
D18S1119
D18S364
D18S1127
D18S69
D18S39
D18S1152
D18S1144
D18S1103
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Chromosome 19
D19S220
D19S420
D19S900
D19S538
D19S903
D19S918
D19S908
D19S219
DM
D19S412
D19S606
D19S902
D19S904
D19S907
D19S553

Figure 6. Results of manual haplotype analysis on chromosome 9. The blue bars
highlight the haplotype that best segregates with disease in the family on this
chromosome. RFS132-7827 and RFS132-5722 lack any portion of the affected
haplotype. (Highlighted by red arrows)
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Figure 7. Results of manual haplotype analysis on chromosome 18. The green
bars highlight the haplotype that best segregates with disease in the family on
this chromosome. RFS132-7827 and RFS132-5722 lack any portion of the
affected haplotype. (Highlighted by red arrows)
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Figure 8. Results of manual haplotype analysis on chromosome 19. The purple
bars highlight the haplotype segregating with disease in the family.
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between D19S907 and D19S553 in RFS132-5722 redefined the telomeric boundary of the
linkage region. The resulting linkage region was still approximately 7.7 Mb in size.
Discussion
Data generated by the Affymetrix SNP array was used in whole-genome linkage
analysis and CNV analysis. CNV analysis did not identify any copy number variants.
Whole-genome linkage analysis identified three linkage regions on chromosome 9, 18, and
19 that warranted additional follow-up based on their maximum multipoint LOD scores of
2.5, 3.5, and 3.8 respectively.
STR markers often have a larger number of differing alleles than SNPs, making them
more polymorphic. The use of these highly polymorphic markers combined with the use of
an extended pedigree provides the fine-point haplotype analysis step with the opportunity to
confirm and refine the linkage regions identified with whole-genome linkage analysis on
SNP data. Examination of the haplotypes generated for chromosomes 9 and 18 showed that
the most prominent haplotype did not appear in each affected family member. Failure of a
haplotype to co-segregate with disease in the family means these two linkage regions cannot
be the disease locus. The most prominent haplotype on chromosome 19 appeared in each
affected family member. Therefore, chromosome 19’s linkage region was confirmed as the
most likely disease locus. Recombination events in RFS132-5721 and RFS132-5722
defined the centromeric and telomeric boundaries of this disease region. There are multiple
possible explanations for the presence of the affected haplotype in unaffected, at-risk
RFS132 family members. Some of these family members might not have started to show
symptoms of RP, especially the youngest generation, since RP has a well-known varying
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age of onset. [1 - 2] Some of these family members may also never show symptoms of RP
as in PRPF31 and RP1’s known cases of incomplete penetrance. [2]
Overall, linkage analysis in RFS132 identified a 7.7 Mb disease region on
chromosome 19q. There are a large number of genes located throughout a region of this
size, and several of these genes are promising candidates for RFS132’s cause of disease.
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Chapter 5: Candidate Gene Sequencing
Introduction
Candidate gene sequencing has played a part in the identification of every known
adRP gene to date. The process allows scientists to incorporate data from multiple sources
to knowledgably select and screen genes that are likely to cause disease based on their
biological relevance to the disease. For example, SNRNP200 was selected as a candidate
gene for the RP33 locus by Zhao et al. 2009. [12] SNRNP200 encodes a U5 small nuclear
ribonucleoprotein (snRNP) 200 kDa helicase involved in the U4/U6 small nuclear RNA
(snRNA) unwinding within the spliceosomal complex. [12] Therefore, SNRNP200’s
functional similarity as a member of the RNA splicing factor protein family to previously
identified adRP genes, such as PRPF8, PRPF3, and PRPF31, made it a strong candidate for
their study. [12] Subsequent sequencing analysis of SNRNP200 resulted in the identification
of adRP disease-causing mutations within the gene. [12]
The next step in my study was to thoroughly characterize the disease region on
chromosome 19q that was identified by linkage analysis of RFS132. Multiple publically
available databases were used to identify the number and nature of the genes located in the
disease region. This information and an extensive literature search were used to help make a
well-informed selection of five candidate genes located within the disease region.
CRX, OPA3, CAPB5, SNRNP70, and SNRPD2, were selected for further analysis
based on their biological relevance to RP. The cone-rod otx-like homeobox (CRX) gene was
selected as a candidate gene based on the previous identification of mutations causing RP,
LCA, and cone-rod dystrophy within the gene. [7, 39] The optic atrophy three (OPA3) gene
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was the second candidate gene selected because it is also a known retinal disease gene with
mutations that result in dominant optic atrophy. [7] Calcium binding protein five’s (CABP5)
retinal specific expression was the primary reason for its selection as the third candidate
gene. [40] Small nuclear ribonucleoprotein 70 kDa (U1) (SNRNP70) and small nuclear
ribonucleoprotein D2 16.5kDa (SNRPD2) are each involved in pre-messenger RNA (premRNA) splicing and were selected as candidate genes for their functional similarity to
known adRP genes such as PRPF3, PRPF8, and SNRNP200. [41 - 42] Sanger sequencing
was used to screen each of these candidate genes for mutations in members of the RFS132
family. Any identified variations were further genetically evaluated for their potential to be
disease-causing.
Methods
Characterization of Linkage Region
Several online genetic databases were used to characterize the chromosome 19q
linkage region. The UCSC Genome Browser (http://www.genome.ucsc.edu/index.html) was
used to identify the total number and location of genes within the linkage region. [43] The
Ocular Genomics Institute’s (Harvard Medical School, Boston, MA) Human Retinal
Transcriptome data (http://oculargenomics.meei.harvard.edu/index.php/ret-trans/110human-retinal-transcriptome) was used to evaluate the retinal expression of the genes
located in the linkage region and locate any novel, retinal specific genes and splicing events.
[44] Several databases, including the 1000 Genomes Browser
(http://browser.1000genomes.org/index.html), dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP/), and the NHLBI Exome Sequencing Project
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Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP):
https://esp.gs.washington.edu/drupal/), were used to help evaluate the frequency and
disease-causing potential of genetic variants identified within the linkage region. [31 - 33]
Data from the ENCODE project, available as tracks within the UCSC Genome Browser, was
used to help select candidate genes and evaluate the disease-causing potential of variants
located in the intronic and regulatory regions of the linkage region. [45]
Selection of Candidate Genes
Five candidate genes, CRX, OPA3, CABP5, SNRNP70, and SNRPD2, were selected
for further analysis on the basis of one or more criteria (Table 3). These criteria include:
known adRP disease-causing genes, associated with another type of retinal disease, high
levels of retinal expression, and/or functional similarity to known adRP disease-causing
genes.
Sequencing
At least two affected and one unaffected member of RFS132 were selected and
screened for mutations in 5 candidate genes, including the complete coding regions of CRX,
OPA3, CABP5, SNRNP70, and SNRPD2 along with the promoter region and 5' and 3'
untranslated regions (UTRs) of CRX. AmpliTaq Gold® 360 Master Mix (Life
Technologies) and M13-tailed primers designed in Primer3 were used to amplify genomic
DNA in a 12.5 µL reaction volume for 35 cycles. [25 - 26] The resulting PCR products
were treated with ExoSAP-IT® (Affymetrix). Purified PCR products were sequenced
bidirectionally with M13 primers and BigDye v1.1 (Life Technologies). Sequence reactions
were purified with BigDye Xterminator® purification kit and run on a 3500 Genetic
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Table 3: Candidate genes located in chromosome 19 linkage region
Gene
CRX
CABP5
OPA3
SNRNP70
SNRPD2

Protein Product
Cone-rod otx-like photoreceptor
homeobox transcription factor
Calcium binding protein 5
Optic atrophy 3 protein
U1 small nuclear ribonucleoprotein
70 kDa
Small nuclear ribonucleoprotein D2
16.5 kDa

37

Reason For Selection
Known adRP gene
Retina specific expression
Known retinal disease gene
Similar function to known adRP
genes
Similar function to known adRP
genes

Analyzer (Life Technologies). Sequence analysis was then performed with SeqScape® v3.0
(Life Technologies).
Results

Characterization of RFS132’s disease region involved revealing the number of genes
located in the region and identifying the exact location, presence of alternate transcripts,
expression, and relation/interaction with other genes of each gene in the region. The UCSC
Genome Browser hg19/February 2009 build places 356 genes in the 7.7 Mb linkage region
on chromosome 19q. Many of the genes located in this gene-rich region are part of large
gene families, and several databases show the presence of alternative transcripts for most of
the genes located in this region. Human retinal transcriptome data from Harvard’s Ocular
Genomics Institute shows that 267 of the 356 genes in the linkage region are expressed in
the retina. A subsequent literature search helped with the prioritization and selection of
candidate genes. Five genes located within the chromosome 19q linkage region were
selected for further analysis (Table 3).
CRX, a known adRP gene cloned by Freund et al. in 1997, was selected as the first
candidate gene. [7, 46] CRX encodes a photoreceptor-specific transcription factor that is
necessary for the differentiation and maintenance of normal rod and cone photoreceptors. [7,
47] Therefore, mutations in this gene result in photoreceptor degeneration and have been
shown to cause RP, LCA, and cone-rod dystrophy. [7, 39] Fifty-four different mutations
have been identified within CRX, and the previous Sanger sequencing, MLPA, and targetedcapture NGS analysis of CRX (discussed in chapter 2) have eliminated the possibility of
these mutations causing disease in RFS132. However, CRX’s distinction as the only
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remaining adRP gene located within the disease locus warrants a confirmation of these
results and expansion of the sequencing analysis completed on CRX.
OPA3, a known retinal disease gene, was selected as the second candidate gene for
analysis. OPA3 encodes a protein in the mitochondrial inner membrane. [7, 48] Mutations
in this gene cause autosomal dominant optic atrophy and cataract (ADOAC) and type III 3methylglutaconic aciduria (MGA) with clinical symptoms that include early-onset bilateral
optic atrophy, urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid, lateronset spasticity, extrapyramidal abnormalities, ataxia, and cognitive deficit. [7, 48 - 49]
CABP5 is part of a subfamily of calcium binding proteins. [40] CABP5’s retinal
specific expression was the main reason for its selection as a candidate gene. [40] A
literature search identified functional studies highlighting CABP5’s possible involvement in
the visual process which strengthened its selection as a candidate gene. Mice lacking
CABP5 exhibit reduced sensitivity in the rod-mediated light responses of their retinal
ganglion cells. [50] These results suggest a role for CABP5 in the transmission of light
through the retina. [50]
SNRNP70 encodes the U1-70kDA snRNP, which is an essential component of the
splicesomal complex. During splicing of pre-mRNA, the U1 snRNP is responsible for
recognizing the 5' splice site. [41] SNRPD2 belongs to a small nuclear ribonucleoprotein
family of proteins that assembles on a conserved sequence in the U1, U2, U4, and U5
snRNAs to help form the core splicesomal complex. [42] Functional similarity to known
disease-causing genes is a common criterion for selection of candidate genes. Therefore,
SNRNP70 and SNRPD2’s participation in the splicing process is the basis of their selection
as candidate genes.
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At least two affected members and one unaffected member of the RFS132 family
were screened for mutations in CRX, OPA3, CABP5, SNRNP70, and SNRPD2 using Sanger
sequencing. Sequencing of these genes included the known coding exons and 15 bps of
intronic sequence at exon/intron junctions. Since CRX is the only known adRP gene located
in the chromosome 19q linkage region, it underwent more extensive screening. For CRX,
500 bps of the 5' promoter region, the 5' and 3' UTRs, and 50 to 100 bps of intronic
sequence at the exon/intron junctions were sequenced. A literature search of CRX also
highlighted additional exons that were subsequently sequenced. [39, 44] Variations from
the reference sequence were further analyzed for the possibility of causing disease. A
variant’s presence among unaffected, ethnically matched controls, identification as a known
polymorphism in online genetic databases such as the 1000 Genomes Browser
(http://browser.1000genomes.org/index.html) and the NHLBI Exome Sequencing Project
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP):
https://esp.gs.washington.edu/drupal/), and/or failure to co-segregate with disease among
additional family members eliminated the variants likelihood to cause disease. [31 - 33]
Sanger sequencing analysis did not reveal any disease-causing mutations among the five
candidate genes analyzed in this family.

Discussion
Genetic databases and information obtained from a literature search were used to
characterize the disease locus on chromosome 19q. Characterizing this region was an
important step towards being able to identify genes with a possible connection to RP.
Identification of these biological connections to RP provides a method for narrowing down
the search for the disease-causing gene from among the 267 retinal expressed genes located
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in RFS132’s disease locus. Sanger sequencing the coding region of each retinal expressed
gene would be an expensive and extremely labor-intensive task that few genetic labs could
undertake. Therefore, focus must be given to the ‘candidates’ deemed most likely to cause
RP.
Di-deoxy capillary electrophoresis sequencing was used to search for the presence of
genetic alterations in CRX, OPA3, CABP5, SNRNP70, and SNRPD2. Any deviations from
the reference sequence of these genes were found to be common, known polymorphisms or
failed to co-segregate with disease in the family. Thus, no disease-causing mutations were
found in the genes selected as likely candidates to cause RP.
Although Sanger sequencing of these candidate genes did not uncover any diseasecausing mutations, this does not fully eliminate these genes as the genetic cause of disease in
RFS132. Genetic variants in the intronic and regulatory regions of these genes that have not
yet been seen may be the underlying cause of this family’s RP. This possibility is addressed
in chapter 6 where my use of whole-exome and whole-genome sequencing to search for
genetic variants in both the coding and non-coding regions of each gene in the chromosome
19q linkage region is discussed. New developments and improvements in sequencing
technologies during the course of this long term project have helped shape the methodology
used for our continued search of RFS132’s disease-causing mutation.
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Chapter 6: Next-Generation Sequencing
Introduction
After using Sanger sequencing to search for RFS132’s disease-causing mutation in
five candidate genes located in the disease locus, NGS technologies were employed to
continue the search. The use of multiple genetic technologies in this study represents the
improvements seen in sequencing technologies during the evolution of this long-term project
and allows us to make use of the benefits that each provides. Sequencing each of the 356
genes located in RFS132’s disease locus is a task that would have once been considered too
costly and too time-consuming to undertake. While candidate gene sequencing allows us to
quickly narrow-in on the genes considered most likely to cause disease, NGS strategies have
provided the opportunity to sequence each gene within the defined disease locus. In fact, the
advantages that NGS technologies provide over more conventional sequencing methods is
turning it into the most popular method of disease-gene identification. [17 – 18]
Why is NGS so popular? NGS has exhibited an impressive molecular diagnosis rate
over the past few years. Currently, the discovery of over 180 novel disease-causing genes
can be attributed to the use of NGS. [16] The massively parallel methods of NGS make it
much faster than conventional sequencing methods. NGS is also much less expensive per
sequence than conventional sequencing methods. NGS allows for direct identification of the
disease-causing mutation while methods such as whole-genome linkage analysis and
genome-wide association studies typically lack the power to identify specific causal
variants. Finally, NGS does not involve the inclusion of any prior knowledge or assumptions
about possible causes of disease like candidate gene sequencing, which might add bias to the
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search for novel disease-causing mutations. Despite all of these advantages, extensive
follow-up analysis is required to identify the disease-causing mutation from among the large
volume of sequencing data produced by NGS.
Whole-exome sequencing was completed on eight members of the RFS132 family
and was used to identify any genetic variation present throughout the coding and splice
regions of their genomes. This was followed by whole-genome sequencing of two members
of the RFS132 family. Whole-genome sequencing was completed to search for genetic
variants among the non-coding regions of their genomes and to add read depth to the regions
already assayed by whole-exome sequencing. A set of discrete filters was then applied to
the large number of genetic variants identified by these NGS strategies to remove the
variants that could not be the cause of disease in this family.
Methods
Whole-Exome Sequencing
Library Preparation
Illumina paired-end libraries were made from 1 µg of DNA according to
manufacturer's protocol with the following modifications: 1) DNA was fragmented into
sizes ranging from 100–500 bp, using a Covaris S2 DNA Sonicator (Covaris Inc., Woburn,
MA) 2) Illumina adapter-ligated DNA was amplified in a single 50 µl PCR reaction for five
cycles, and 3) solid phase reversible immobilization (SPRI) bead cleanup was used to purify
the PCR amplification and select for fragments 300–500 bp in size.
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Exome Capture
Sequencing libraries were hybridized with either a customized Agilent SureSelect
All Exome Kit v2.0 (Agilent Technologies, Santa Clara, CA) or the Nimblegen SeqCap EZ
Human Exome Library v2.0 (Table 4), according to the manufacturer's protocol. The KAPA
SYBR FAST qPCR Kit (KAPA Biosystems, Woburn, MA) was used for library
quantification. Libraries were quantified using PicoGreen prior to paired-end sequencing
(2x100 bp) on Illumina GAIIx or HiSeq2000 instruments.
Sequence Alignment and Variant Calling
Illumina reads passing instrument QC were aligned to the GRCh37-lite reference
sequence with Burrows-Wheeler Aligner (BWA) v0.5.9 (http://bio-bwa.sourceforge.net/).
[51] Parameters –t 4 –q 5 (where t is the number of threads and q is the parameter for read
trimming) were passed to the bwa aln command, and default parameters were used for other
commands. [51] Duplicates were marked by Picard v1.46
(http://picard.sourceforge.net/index.shtml). Putative single-nucleotide variants (SNVs) were
called using VarScan v2.2.9 (http://varscan.sourceforge.net/index.shtml) with parameters -min-coverage 3 --min-var-freq 0.20 --p-value 0.10 --strand-filter 1 --map-quality 10 and
SAMtools v0.1.16 (http://samtools.sourceforge.net). [52 - 53] False positives were removed
as previously described in Koboldt et al. 2012. [52] Small insertion/deletion variants
(indels) were called by VarScan v2.2.9 with the same parameters and false-positive filtering.
[52]
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Table 4. Exome sequencing data. The exome kit, total number of reads (Illumina 2x100 bp protocol), mapping rate,
duplication rate, total sequenced data, and exome target coverage at 20x and 1x are provided. A “*” highlights the
unaffected spouse.
Sample
RFS132-5721
RFS132-7467
RFS132-7472
RFS132-7827
RFS132-7473
RFS132-5948*
RFS132-5949
RFS132-5463

Exome Kit
Nimblegen v2
Nimblegen v2
Nimblegen v2
Nimblegen v2
Agilent v2b
Agilent v2b
Agilent v2b
Agilent v2b

Reads
122,509,234
107,049,676
95,077,414
73,681,406
230,730,994
218,628,518
223,637,628
241,894,124

Mapped
121,017,610
105,665,194
93,874,908
72,817,044
226,027,730
208,132,924
210,149,218
226,045,728

Map Rate
98.78%
98.71%
98.74%
98.83%
97.96%
95.20%
93.97%
93.45%
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Dup Rate
23.67%
25.79%
27.81%
20.37%
20.61%
21.09%
24.15%
21.65%

Total Gbp
12.25
10.70
9.51
7.37
23.07
21.86
22.36
24.19

Coverage at 20x
93.76%
91.25%
89.08%
80.89%
80.82%
75.70%
74.26%
76.58%

Coverage at 1x
99.29%
99.29%
99.17%
98.83%
96.51%
94.39%
94.51%
95.29%

Variant Compilation and Annotation
Cross-sample variant call format (VCF) files were generated for each variant type
(SNVs and indels). Sites that failed the false-positive filter in >50% of samples in the family
were removed as probable artifacts. Missing genotypes were backfilled using SAMtools
consensus calling (samtools pileup –c). [53] Variants were annotated with information from
the dbSNP build 137 VCF file using the vcf-annotate command of the joinx tool
(http://gmt.genome.wustl.edu/joinx/1.6/). [33] Known dbSNP variants in the VCF were
updated with RefSNP (RS) number in the ID column, as well as global minor allele
frequency (GMAF) and mutation/clinical status (PM/OMIM/LSDB) in the INFO column.
[33] Variants were also annotated with gene structure information using internal software
(and Ensembl release 70) as well as the Variant Effect Predictor (VEP) v2.2 with
parameters: --condel b --polyphen b --sift b --hgnc --canonical. For each gene, the canonical
VEP annotation was used whenever possible. In the event multiple overlapping genes
yielded different annotations, the most damaging annotation was used. In coding regions,
the priority order (from most damaging to least damaging) was: frameshift, nonsense,
essential splice site, missense, nonstop, synonymous coding. Missense variants were
considered damaging if called as such by at least one of Polyphen (Polymorphism
Phenotyping, http://genetics.bwh.harvard.edu/pph2/index.shtml) (“probably_damaging” or
“possibly_damaging”), SIFT (Sorting Intolerant from Tolerant, http://sift.jcvi.org/)
(“deleterious”), or Condel (CONsensus DELeteriousness, http://bg.upf.edu/condel/home)
score of missense SNVs (“deleterious”). [54 - 56]
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Whole-Genome Sequencing
Library Preparation
Illumina sequencing libraries were constructed with 1µg of genomic DNA according
to the manufacturer’s protocol (Illumina Inc.) with the following modifications: 1) DNA was
fragmented using a Covaris E220 DNA Sonicator (Covaris, Inc.) to range in size between
100 and 400bp 2) Illumina adapter-ligated library fragments were amplified in four 50µL
PCR reactions for 18 cycles and 3) SPRI bead cleanup was used for enzymatic purification
throughout the library process, as well as final library size selection targeting 300-500bp
fragments.
Sequence Alignment and Variant Calling
Paired-end sequencing (2x100 bp) was performed on an Illumina HiSeq2000
instrument and processed with Illumina sequencing pipeline software version 1.3. Reads
were aligned to the human reference assembly (GRCh37-lite) with BWA v0.5.9 using
parameters -t 4 -q 5. [51] Duplicates were marked using Picard v1.46. SNVs were called
using VarScan v2.2.9 with parameters --min-coverage 3 --min-var-freq 0.20 -p-value 0.10 -strand-filter 1 and SAMtools v0.1.16 with default parameters. [52 - 53] SNVs from the
union of these callsets were filtered to remove systematic false positives as previously
described in Koboldt et al. 2012. Indels were called in an identical fashion, except that
SAMtools was not used.
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Variant Compilation and Annotation
Variant Compilation and Annotation was completed as described above for wholeexome sequencing.
Filtering of NGS Variants
After annotation of all SNVs and indels identified by whole-exome and wholegenome sequencing, a set of filters was applied to the list of genetic variants in order to
remove those that could not be the cause of disease. These filters included: located in the
chromosome 19q disease locus; minor allele frequency (MAF) less than 1%; minor allele
count (MAC) less than 5; segregates with disease in the family. Variants that did not pass
each of these filters were removed from the list of possible disease-causing variants.
Results
In a collaborative effort with our peers at the Genome Institute at Washington
University in St. Louis, MO, seven affected family members and one unaffected spouse
from the RFS132 family underwent exome capture and next-generation sequencing on an
Illumina platform. Approximately 14.4 Gbp of sequence was generated per individual.
(Table 4) The mapping rate and duplication rate of each individual for this sequencing data
can be found on Table 4. On average, 98% of the 34 Mbp of targeted coding sequence was
covered by at least one read, and approximately 89% was covered by at least 20 reads.
Variant calling identified 211,651 SNVs and 41,171 indels in one or more of the
individuals sequenced. A series of filters was applied to this list of variants to remove those
that are not the cause of disease in this family. Mapping data discussed in chapter 4 was
used to filter out all variants that were not located in the chromosome 19q disease locus.
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Variants present in online genetic databases such as the 1000 Genomes Browser
(http://browser.1000genomes.org/index.html) and the NHLBI Exome Sequencing Project
Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP):
https://esp.gs.washington.edu/drupal/), and/or dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP/) with a MAF of 1% or greater were also
removed from the list of possible disease-causing variants. [31 - 33] Next, MAC’s were
hand-curated from the same online genetic databases and used to remove the variants that
have a MAC of five or greater from the list of possible disease-causing variants. A MAC of
5 was chosen as the cutoff to help account for the fact that rare and disease-causing alleles
are being increasingly located in databases such as dbSNP. I can also not completely
exclude the possibility that some of these databases may contain genetic information from
an RP patient. The final filter involved eliminating the variants that did not segregate with
disease among the family members sequenced. One important caveat to note about this final
filter is that it was only applied to variants that were not seen in each affected individual
AND reached a read depth of 20x in every individual for the bp position being considered.
This caveat also extended to variants that were present in ONLY the unaffected spouse. The
caveat was applied to ensure that low coverage at any particular position did not prevent us
from seeing the rare allele in at least one individual and, therefore, unnecessarily eliminating
a potential disease-causing mutation. Application of each of these filters narrowed the list of
possible disease-causing variants identified by whole-exome sequencing down to 163 SNVs
and 82 indels.
Two affected members of the RFS132 family underwent whole-genome sequencing
on an Illumina platform at Washington University’s Genome Institute. These two
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individuals, RFS132-5721 and RFS132-5463, were chosen for sequencing based on the
availability of enough high quality DNA and appropriately consented individuals. For
sample RFS132-5721, 1.47 billion paired-end reads were generated. Of the total paired-end
reads generated, 94.93% were mapped to the reference sequence and 4.18% were marked as
duplicates, yielding 44.49x average haploid coverage. For sample RFS132-5463, 1.07
billion paired-end reads were generated. However, only 19.32x haploid coverage was
achieved due to a low mapping rate (66.7%) and elevated duplication rate (7.03%), likely
the result of low quality DNA. The same set of filters was applied to all the variants
identified by whole-genome sequencing. Additionally, variants that were already seen from
whole-exome sequencing were removed to avoid repeat variants as the two lists would
eventually be combined. Removal of all genetic variants already seen in whole-exome
sequencing and variants not present in the chromosome 19q disease locus narrowed the list
of variants to 260 SNVs and 185 indels. Application of the final three filters further
narrowed the list of whole-genome sequencing variants to 106 SNVs and 164 indels.
Discussion
Multiple NGS strategies were used to identify the full of array of genetic variation
located in RFS132’s chromosome 19q disease locus. Whole-exome sequencing was used to
focus on identification of genetic variants in the coding and splice regions of the genome as
this is where the majority of currently known RP mutations lie. Whole-genome sequencing
was subsequently employed to identify any genetic variants located in the non-coding
regions of the genome. Whole-genome sequencing was also used to avoid artifacts
introduced by exome capture and add sequencing read depth to the regions assayed by
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whole-exome sequencing in an effort to identify any variants missed by whole-exome
sequencing.
These two NGS methods successfully identified thousands of coding and non-coding
variants. The disease-causing mutation for RFS132’s adRP should be present in the mapped
disease locus and present in the heterozygous state of each affected family member. Since
RP is a rare disease, the disease-causing mutation should also be a rare variant that is not
present in unaffected controls. Therefore, a set of filters was applied to this large list of
genetic variants to remove variants that were: 1) not located within the mapped disease locus
2) had a MAF of 1% or greater 3) had a hand-curated MAC of 5 or greater and 4) not
segregating with disease in the sequenced family members. Variants that did not pass these
filters should not be the cause of disease in RFS132.
After application of the filters, 269 SNVs and 264 indels remained on our list of
possible disease-causing variants. These are rare variants located in the disease locus and
segregating with disease in the family members sequenced. With so many variants still
remaining, additional genetic and bioinformatics analyses are necessary to determine if one
(or more) of these variants is RFS132’s disease-causing mutation. Chapter 7 will discuss the
steps taken to evaluate the potential pathogenicity of the remaining variants.
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Chapter 7: Genetic and Bioinformatic Follow-up of Next-Generation
Sequencing Variants
Introduction
NGS has seen a continual stream of improvements and growth in applicable uses.
The ability to quickly screen a patient’s entire genome provides great opportunities for
scientists in the identification of novel disease-causing genes. The cost of NGS also makes
these methods available to a large number of scientists.
However, it is the elucidation of the specific disease-causing mutation from among
the data produced by NGS that is slowing down disease-gene identification. Many scientists
struggle under the weight of the large amount of data produced by NGS. The pathogenic
allele must be identified from among the numerous non-pathogenic polymorphisms and
sequencing errors. The complex nature of the transcriptome increases the difficulty of
delineating biological causation. Rare genetic diseases can only provide us with a small
number of patients to study. Genetically heterogeneous diseases introduce the possibility of
the remaining disease-causing mutations being family-specific. This lowers the opportunity
of confirming pathogenicity in additional families with the same disease.
There is currently no set method for overcoming these complications and identifying
the disease-causing mutation from among the large amount of data produced by NGS. This
chapter discusses the additional genetic and bioinformatic steps I have taken to evaluate the
pathogenic potential of the remaining 269 SNVs and 246 indels identified by NGS. The
variants were verified in a subset of the RFS132 family using Sanger sequencing, still
considered the gold standard of sequencing, in order to remove those that were false
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positives, paralogous variants, or not segregating with disease. After verification, the
remaining variants were sequenced in all 28 members of the family to test, once again, for
appropriate segregation with disease. The final set of remaining rare variants were then
evaluated, to varying degrees, for their presence in additional adRP families, their location
in a gene expressed in the retina, the occurrence of different mutations in the same gene for
additional adRP families, and the effect they induce on the gene’s protein.
Methods
Sanger Sequencing
AmpliTaq Gold® 360 Master Mix (Life Technologies) and M13-tailed primers
designed in Primer3 were used to amplify genomic DNA in a 12.5 µL reaction volume for
35 cycles. [25 - 26] The resulting PCR products were treated with ExoSAP-IT®
(Affymetrix). Purified PCR products were sequenced bidirectionally with M13 primers and
BigDye v1.1 (Life Technologies). Sequence reactions were purified with BigDye
Xterminator® purification kit and run on a 3500 Genetic Analyzer (Life Technologies).
Sequence analysis was then performed with SeqScape® v3.0 (Life Technologies).
Results
Verification of NGS Variants
The remaining 269 SNVs and 246 indels were Sanger sequenced in two affected
individuals and one unaffected spouse in the RFS132 family and analyzed with Life
Technologies SeqScape® software v3.0. PCR primers were designed to include at least 50
additional bps on either side of the variant being sequenced in order to improve the quality
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of the sequence seen at the variant location. Validation of these variants was necessary to
remove those that were false positives, paralogous variants, or not segregating with disease
in the family members sequenced. Verification efforts removed all but 64 SNVs and 3
indels from the list of possible disease-causing variants. There were also 16 additional
variants that I was unable to verify. My inability to use Sanger sequencing to verify each of
these 16 variants was due to the extremely repetitive nature of where these variants were
located (Figure 9).
Analysis of NGS Variants in the Entire Family
After verifying that the remaining 64 SNVs and 3 indels were true genomic variants,
they were Sanger sequenced in all 28 members of the RFS132 family (Figure 4). This was
used for verification that each variant segregated with disease in the family. Although
previously discussed analyses showed that each of these variants segregated with disease in
the family members sequenced, verification of these results in the entire family provides
important additional information. The unaffected spouses offer additional ethnically
matched control samples. Also, some family members had varying sizes of the affected
haplotype (Figure 8). These rare variants provide an additional opportunity to redefine the
boundaries of the disease locus. Four variants failed to segregate with disease in RFS1325722. This affected family member also has the recombination that defines the telomeric
boundary of the disease locus. Therefore, these four variants were found to be nonpathogenic and used to redefine and narrow the telomeric boundary of the disease locus
(Figure 10). A C > T SNV in the intron of KLK15 at 51,334,646 bps now sets the telomeric
boundary of the disease locus and narrows the disease locus by 215,386 bps and 13 genes.
The remaining 63 variants segregated with disease in all available members of the
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A)

B)

Figure 9. Repetitive regions of the disease locus. A and B
show electropherograms of repetitive regions where NGS
indicated variants were located. The inability to confidently
sequence all the way through these repetitive regions
prevented the putative NGS variants located here from
being verified.
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215,386 bps
and
13 genes
Figure 10. Use of NGS variants to redefine the disease locus boundaries.
The identification of 4 NGS variants that did not segregate with disease in
RFS132-5722 allowed the disease locus to be narrowed by 215, 386 bps and
13 genes.

56

RFS132 family.
Analysis of Rare NGS Variants Segregating with Disease in the Family
The final 63 variants are rare SNVs or indels identified by NGS that have been
verified as real genomic variants and shown to segregate appropriately with disease in the
entire RFS132 family. These variants include a variety of variant classes spread throughout
the disease locus (Table 5). Only one of these variants, a synonymous SNV in SYMPK, is
located in the protein-coding region of a gene. Therefore, priority was given to this variant
for additional follow-up analysis.
Symplekin (SYMPK) encodes a nuclear protein involved in the regulation of
polyadenylation and promotion of gene expression. [57] SYMPK is believed to serve as a
scaffold for recruiting regulatory factors to the polyadenylation complex. [57] SYMPK also
participates in 3' processing of replication-dependent histone mRNAs, which do not undergo
polyadenylation. [57] The NGS variant identified in SYMPK is a synonymous C > T SNV
located at 46,334,722 bp (Figure 11). This synonymous SNV changes the codon of the
Leucine located at the 506th amino acid of the SYMPK protein. Previous analysis in chapter
6 shows this variant is not present in any online genetic databases such as the 1000 Genomes
Browser and dbSNP. This variant was then Sanger sequenced in an additional 96 ethnically
matched controls to search for the presence of this variant in individuals that do not have
RP. The SYMPK SNV was not found in any of the individuals sequenced. Next, the entire
SYMPK gene was Sanger sequenced in 83 individuals from families that have been
diagnosed with adRP. These families are part of a well-characterized and previously
described adRP cohort in which all known causes of adRP have been eliminated. [15] This
step was completed to search for the presence of this variant or any other variant in
57

Table 5. Classification of NGS variants
Variant Class
Synonymous
5' UTR
3' UTR
Intronic
Intergenic

Number of SNVs
1
2
7
43
7
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Number of Indels
0
0
0
2
1

Figure 11. Synonymous SYMPK SNV
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additional families with adRP. Identification of SYMPK mutations in additional families
would have greatly strengthened the pathogenic potential of this variant. However, I was
unable to find this variant or any others in the SYMPK gene in the 83 families sequenced.
This novel SYMPK SNV was then analyzed in silico to help determine the likelihood
of it being a pathogenic mutation. Retinal transcriptome data shows that each exon of
SYMPK is well-expressed in the retina. [44] This transcriptome data also shows that there
are no retinal-specific exons or splice junctions located in this gene. [44] Alternate
transcripts of SYMPK place this SNV in the terminal exon, which could be significant if
there is any alternative splicing or alternative 3' polyadenylation taking place in this gene in
RFS132. The SNV occurs at a well-conserved bp position in the gene (Table 6). SpliceAid
Anlysis (http://www.introni.it/splicing.html) indicates the SYMPK SNV destroys an
hnRNPA1 (heterogeneous nuclear ribonucleoprotein A1) binding site. [58] Many of these
hnRNPs are implicated in splicing as they bind to pre-mRNA before assembly of the
splicesome. [59] More specifically, studies indicate hnRNPA1 is involved in U2AF
mediated 3' splice site recognition. [59] All of this information together suggests the
possibility of alternative splicing taking place in individuals with this variant. Additional in
vitro studies will be necessary to confidently determine the effect the SYMPK SNV has on
the SYMPK transcript in the RFS132 family. However, more studies might be premature
with 62 additional variants segregating with disease in this family.
The 63 rare NGS variants segregating with disease in this family can be found in
Table 7. Each of these variants received varying degrees of the same follow-up analyses
completed on the SYMPK SNV. Multiple biological properties were taken into account
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Table 6. Conservation of the synonymous SYMPK variant
Organism
Human
Chimp
Gorilla
Orangutan
Baboon
Tree shrew
Mouse
Guinea pig
Squirrel
Rabbit
Dolphin
Cow
Horse
Cat
Dog

DNA Sequence
GTGGGTTCCCTGAGCTCCATGTC
GTGGGTTCCCTGAGCTCCATGTC
GTGGGTTCCCTGAGCTCCATGTC
GTGGGTTCCCTGAGCTCCATGTC
GTGGGTTCCCTGAGCTCCATGTC
CTGGGCTCCCTGAGCTCCATGTC
GTAGGCTCTCAGAGCACCATGTC
GTGGGCTCTCTGAGCTCCATGTC
GTGGGCTCTCTGAGCTCCATGTC
GTGGGGTCCCTGAGCGCCATGTC
GTGGGCTCCCTGAGCTCCATGTC
GTGGGCTCCCTGAGCTCCATGTC
GTGGGCTCCCTGAGCTCCATGTC
GTGGGCTCCCTGAGCTCCATGTC
GTGGGCTCCCTGAGTTCCATGTC
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Table 7. NGS variants segregating with disease in RFS132
BP
Position

REF

ALT

dbSNP ID

Variant
Class

Variant Gene

A

rs67507730

intronic

SRRM5

G
G
A
G
T
C
A
T
A

rs4251908
.
rs182300049
rs113715157
rs185907451
rs184945473
.
.
.

intronic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
3' UTR

PLAUR
ZNF226
ZFP112
ZNF285
CEACAM22P
IGSF23
PVR
BCL3
BCAM
ENSG0000026
7282
CLASRP
PPM1N
VASP
VASP
VASP
VASP
OPA3
GIPR
SIX5

44,157,037
44,676,922
44,865,824
44,901,201
45,116,478
45,130,502
45,162,594
45,251,743
45,324,374

ACTGGC
ACCCAG
TAGATT
CC
A
A
T
A
A
G
G
C
T

45,392,527

A

G

.

intronic

45,563,561
46,005,597
46,011,052
46,020,678
46,024,787
46,024,912
46,031,983
46,182,003
46,270,818

C
A
C
G
C
C
C
G
G

T
C
G
T
T
T
A
A
A

.
.
.
.
rs192868401
.
rs182553559
rs184478662
.

intronic
3' UTR
intronic
intronic
intronic
intronic
3' UTR
intronic
intronic

44,112,426
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Comments
Overlaps with an intron of ZNF428 on the antisense
Strand

AFR MAC in 1000 Genomes: 4
Low retinal expression; AFR MAC in 1000 Genomes: 3
Low retinal expression; AFR MAC in 1000 Genomes: 4

AFR MAC in 1000 Genomes: 1
AFR MAC in 1000 Genomes: 3
AFR MAC in 1000 Genomes: 1

46,331,268

G

A

.

intronic

SYMPK

46,334,722

C

T

.

synonmous

SYMPK

46,341,285
46,351,421
46,545,943
46,582,514
46,582,726
46,623,858
46,626,912
47,192,657
47,216,922
47,225,866
47,227,890
47,234,613
47,235,891
47,241,023
47,546,304
47,603,149
47,634,429
47,998,467
48,052,265
48,205,788
48,245,113
48,248,317
48,848,708

T
G
A
T
C
A
T
G
A
C
G
C
C
C
C
T
G
T
G
C
A
C
T

C
A
G
C
T
G
G
A
G
T
A
T
T
T
T
C
A
A
A
T
T
T
C

.
.
rs148383368
.
.
.
rs143430345
.
rs115121958
.
.
rs115655565
rs116745685
rs116286078
.
rs186045365
.
.
rs10417667
.
.
rs183699501
rs111791335

intronic
intronic
intergenic
intergenic
intergenic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
intronic
3' UTR
3' UTR
intergenic
intronic

SYMPK
SYMPK
.
.
.
IGFL3
IGFL3
PRKD2
PRKD2
STRN4
STRN4
STRN4
STRN4
STRN4
NPAS1
ZC3H4
SAE1
NAPA
ZNF541
GLTSCR1
EHD2
.
TMEM143

48,949,049

C

G

.

5' UTR

GRWD1
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Splicing Aid Analysis: eliminates an hnRNP A1 binding
site

AFR MAC in 1000 Genomes: 2

Low retinal expression
Low retinal expression; AFR MAC in 1000 Genomes: 4
AFR MAC in 1000 Genomes: 4

AFR MAC in 1000 Genomes: 4
AFR MAC in 1000 Genomes: 4
AFR MAC in 1000 Genomes: 2

Low retinal expression

ENCODE:Histone:H2AZ,Histone:H2BK120ac,Histone:H
2BK20ac,
Histone:H2BK5ac,Histone:H3K18ac,Histone:H3K27ac,

Histone:H3K27me3,Histone:H3K36ac,Histone:H3K4ac,
Histone:H3K4me2,Histone:H3K4me3,Histone:H3K56ac,
Histone:H3K9ac,Histone:H4K5ac,Histone:H4K8ac,
Histone:H4K91ac,OpenChromatin:DNase1,
OpenChromatin:FAIRE,Polymerase:PolII,
TranscriptionFactor:CBP,TranscriptionFactor:CTCF,
TranscriptionFactor:Cmyc,TranscriptionFactor:E2F1,
TranscriptionFactor:E2F4,TranscriptionFactor:ELF1,
TranscriptionFactor:ETS1,TranscriptionFactor:Gabp,
TranscriptionFactor:HDAC1,TranscriptionFactor:HEY1,
TranscriptionFactor:Max,TranscriptionFactor:SIX5,
TranscriptionFactor:Sin3Ak20,TranscriptionFactor:TAF7,
TranscriptionFactor:Yy1,TranscriptionFactor:ZBTB33
49,015,119
49,533,770
49,593,153
50,097,088

G
C
C
C

A
T
T
T

.
.
rs190028492
.

intronic
intergenic
intronic
intronic

LMTK3
.
SNRNP70
PRR12

50,270,285

C

G

.

5' UTR

AP2A1

50,354,289
50,367,424
50,655,625
50,657,268

G
G
T
G

A
A
C
C

.
.
.
.

intronic
intronic
intergenic
intronic

PTOV1
PNKP
.
IZUMO2

64

AFR MAC in 1000 Genomes: 3
ENCODE:Histone:H3K27ac,Histone:H3K27me3,
Histone:H3K4me2,Histone:H3K4me3,
Histone:H3K9ac,OpenChromatin:DNase1,
Polymerase:PolII,TranscriptionFactor:Cfos,
TranscriptionFactor:E2F4,
TranscriptionFactor:ELF1,
TranscriptionFactor:Gabp,
TranscriptionFactor:Pbx3,
TranscriptionFactor:SP1,
TranscriptionFactor:SP2,
TranscriptionFactor:Sin3Ak20

Low retinal expression

50,818,774
50,819,228
50,927,298
50,969,387

G
G
G
C

51,114,887

T

51,124,773
51,168,591
51,206,017

C
T
G

A
C
A
T
TTTT
A
T
TG
C

.
.
.
.

3' UTR
3' UTR
intronic
intronic

KCNC3
KCNC3
SPIB
MYBPC2

.

intergenic

.

.
.
.

intergenic
intronic
intronic

.
SHANK1
SHANK1
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Low retinal expression

when evaluating the pathogenic potential of these variants and the need for additional
analysis. Several of these variants have MAC’s that are above zero and below five. While
these variants are not novel, they are below the previously discussed MAC filter of five or
greater (Chapter 6). Since the online genetic databases that we used to evaluate the
frequency of these variants are more biased towards whole-exome sequencing data, it is
possible these variants occur in the population at a frequency greater than databases
currently suggest. Reaching out to collaborators with access to large whole-genome
sequencing studies can help determine how polymorphic these variants truly are.
Discussion
NGS has provided unprecedented ability to detect genetic variants throughout an
individual’s genome. However, the ability to detect more variants is increasing the
difficulty of determining which of those variants is pathogenic. In this chapter, the
pathogenic potential of the 269 SNVs and 246 indels that passed filtering in chapter 6 was
evaluated.
Sanger sequencing was used to verify whether any of these variants were false
positives, paralogous variants, or failing to segregate with disease. This narrowed the list of
candidate variants down to 67. Sanger sequencing is capable of producing much longer
sequencing read lengths than those typically used in NGS platforms. These longer reads
provide greater specificity to regions of the genome and enabled detection of false positives
and paralogous variants. Additional segregation analyses in the remaining RFS132 family
members identified four SNVs that failed to segregate with disease in RFS132-5722. This
information was used to redefine the boundaries of our disease locus and narrow the critical
region to 7.5 Mb and 343 genes.
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A total of 63 rare variants segregating with disease were identified by NGS in the
RFS132 family. These variants are spread throughout the disease locus and are in a variety
of variant classes. Genetic and bioinformatic analyses were completed to evaluate these
variants’ potential to be disease-causing. Priority was place on the SYMPK variant because
it is the only one located in a protein-coding region. Additional in vitro studies are
necessary to confidently determine the likelihood of any of these variants causing disease in
RFS132. However, with 63 candidate variants remaining, this list is likely too extensive for
in vitro studies to be completed on each one.
Data sharing efforts have been initiated with scientists studying RP across the
country. RP is a rare genetic disease, and the remaining adRP disease-causing variants may
be extremely rare and/or private variants. Therefore, we have asked these researchers to
search for the presence of any of the remaining 63 NGS variants (or variants within the same
genes) in adRP families available to them in their lab in addition to our screening of the
families available in the Daiger laboratory. Identification of one of these NGS variants
would greatly increase its priority for follow-up analysis.
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Chapter 8: Conclusions and Future Directions
Advancement of RP Research
RP research has seen great success over the past two decades. Sixty-three genes
have been shown to cause RP and over 3,100 mutations have been identified among these
genes. [5, 7] The tools used for disease-gene discovery have also improved and become
more powerful, notably the advent of NGS. With the continual identification of new
disease-causing genes and advances in genetic technologies, many hope and predict that it
will be possible to detect the genetic cause of disease in 95% of RP patients within the next
five years. [5]
Continuing towards the goal of molecular diagnosis in 100% of known RP patients is
extremely important because accurate molecular diagnosis is an essential step in the
development of treatments for these RP patients. Identification of the remaining diseasecausing genes will help improve our understanding of the visual process by identifying any
additional biological pathways involved in RP. This is specific information that can be used
in the management and treatment of the vision loss seen in RP patients. For example,
Bowne et al. 2011 identified the first dominant-acting RP mutation in RPE65, a gene in
which recessive RP and recessive LCA mutations had already been identified. [14] AAVmediated gene-replacement therapy had already successfully treated LCA patients with
recessive RPE65 mutations. [14] Therefore, similar treatment methodology is likely to be
successful in treating RP patients with dominant RPE65 mutations. [14] It is an exciting
time in research when identification of a patient’s mutation can quickly and directly lead to
treatment of their life-altering disease.
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Summary of Results
Despite the already large number of genes associated with RP, our search for novel
disease-causing genes is not complete. Disease-causing mutations have not been identified
in 30-35% of patients with adRP. [5] The goal of my research is to increase the number of
known genes associated with adRP. RP is extremely genetically heterogeneous, and it is
unknown how often the remaining disease-causing mutations will appear in the RP
population. Therefore, I have taken a family-by-family approach in identifying novel adRP
genes and have used a multitude of advanced genetic techniques to search for the diseasecausing gene and mutation in an African American family referred to as RFS132. This
systematic and thorough process is also quite circular (Figure 3). Each new piece of
information involves a re-evaluation of what we know at all of the previous steps and feeds
into how we approach the following steps.
RFS132 was enrolled in this study after the family’s proband received a clinical
diagnosis of adRP for his vision loss. Informed consent and DNA samples were obtained
from a total of 28 members of this muti-generational African American family. Seven
family members received comprehensive visual function exams that highlighted the varying
degrees of severity in their symptoms. The visual exams also displayed their poor visual
acuity, elevated dark-adapted thresholds, and significant loss of rod and cone
photoreceptors. Each of these symptoms is consistent with a diagnosis of RP, and they will
provide possible guidance for identifying the disease-causing mutation once candidate
variants have been identified.
Since a total of 23 genes are already known to cause adRP, it was imperative to
evaluate and eliminate all known causes of adRP in this family. Sanger sequencing was
69

used to screen the exons and exon/intron junctions of the known adRP genes. MLPA was
used to screen for CNVs and genomic rearrangements that might be missed by conventional
sequencing methods in a subset of the known adRP genes. Targeted capture NGS was used
to screen the exons and splicing regions 48 RP genes and 115 additional retinal disease
genes. Each of these methods was unable to identify a potential disease-causing mutation in
the known causes of adRP. Additionally, all NGS variants identified by whole-exome and
whole-genome sequencing in known adRP genes, including intronic and regulatory variants,
were evaluated and eliminated as the possible cause of disease.
Whole-genome linkage analysis followed by fine-point haplotype analysis using
STR markers and rare NGS variants mapped RFS132’s disease locus to a 7.5 mega-base
region on chromosome 19q. A total of 343 genes are located in this disease locus of which
254 are expressed in the retina. CNV analysis, using data generated from an Affymetrix 6.0
SNP array, did not identify any copy number variants.
Five candidate genes, CRX, OPA3, CABP5, SNRNP70, and SNRPD2, located
within this disease locus were chosen as likely candidates to cause disease based on their
biological relevance to RP. Sanger sequencing was used to screen these genes for possible
disease-causing mutations.
Whole-exome sequencing and whole-genome sequencing were used to identify all of
the genetic variants located in the chromosome 19q disease locus. These NGS strategies
identified 63 rare variants located throughout the disease locus that segregate with disease in
the entire family. Additional genetic and bioinformatic analyses were completed to evaluate
these variants’ potential to be disease-causing. Each of these 63 variants is still a candidate
for RFS132’s disease-causing mutation. Priority is placed on the synonymous SYMPK SNV
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as it is the only variant located in the coding region of a gene. Even though it is
synonymous, in silico analysis indicates this SNV destroys an hnRNP A1 binding site.
Future Directions
Despite significant effort and the use of multiple genetic technologies, I have not yet
been able to single-out RFS132’s disease-causing mutation. However, the wealth of
detailed genetic information produced in this study should be used to continue the search for
this family’s disease-causing gene. Identifying the genetic cause of RFS132’s adRP will
provide the family with information that can be used in a more accurate and thorough
diagnosis and prognosis of their disease. This information will also be beneficial to any
other families identified with mutations in the same gene.
The first step in moving forward is outlining each of the reasons that may have
prevented the confident identification of RFS132’s disease-causing mutation. These reasons
are as follows: 1) The disease-causing mutation is not on chromosome 19. 2) We dismissed
the disease-causing mutation as non-pathogenic during the course of this study. 3) The
disease-causing mutation is one of the variants segregating with disease. 4) The diseasecausing mutation is in a region that is poorly covered by NGS, and the rare, disease-causing
allele was never seen. 5) The disease-causing mutation is not detectable by current
sequencing technologies. I feel the first two of these reasons are the least likely. Wholegenome linkage analysis identified three different chromosomal regions with a positive LOD
score. These results were confirmed and refined with an additional genetic technique, finepoint haplotype analysis. Generating haplotypes for each of these chromosomal regions
showed only one chromosomal region with a haplotype that tracked with disease. I also feel
it is unlikely that the pathogenic variant was dismissed as non-pathogenic during the course
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of this study. Every attempt was made to be conservative with the filters and elimination
criteria applied to my data.
The third possible scenario is that one of the 63 rare variants identified by NGS is the
cause of disease. I am not alone in the struggle to pinpoint the disease-causing mutation
from among the large amount of genetic data that I have laboriously produced. Multiple
reviews cite identification of the pathogenic allele as the ‘rate-limiting’ step in the analysis
of NGS data. [16 – 18] While many studies proceed toward functional validation after a list
of candidate variants is identified, I feel there are still too many possible candidates for
functional validation and would be an unwise use of time and resources. Priority should be
placed on narrowing the disease locus and searching for overlapping candidate variants
among additional adRP families. I detail each of these suggestions later on.
The final possibilities to consider are that the disease-causing mutation is in a region
poorly covered by NGS or the disease-causing mutation is not detectable by current
sequencing technologies. Both of these would mean that the disease-causing mutation has
not yet been seen. The 20x read depth coverage and mapping rates found in Table 4 and in
the results section of chapter 6 indicates that both of these are viable options.
Computational methods have a difficult time confidently mapping the relatively short NGS
reads to repetitive regions of the genome. NGS and conventional sequencing methods also
have a difficult time detecting certain types of mutations, such as large deletions and
rearrangements. Despite our use of CNV analysis, MLPA, and NGS strategies, it is possible
we have missed some of these large deletions or genomic rearrangements. Tucker et al’s
2011 identification of a homozygous Alu insertion in a MAK (male germ cell-associated
kinase) exon as the cause of RP in an isolated individual is a prime example of why these
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mutation types should not be over-looked. As sequencing technologies continue to improve,
our ability to detect these mutation types will increase.
I feel one of the most valuable sources of information for the future of this study lies
within the family members’ genetic and clinical information. It has already been mentioned
that working with the family is an ongoing process. It is extremely important to encourage
and assist more members of the family in getting thorough visual function exams. RP’s
varying age of onset also makes it important to update the exams of those that have already
been seen before. Figure 8 shows several unaffected, at-risk family members have smaller
pieces of the current disease locus. If any of these individuals’ disease status is updated
from at-risk to affected, we would be able to narrow the genomic region in which we are
searching for the disease-causing gene. There are also additional younger members of this
family that can still be enrolled in this study. Each of those with an affected parent has a
50% chance of developing RP. Each of these also has a possibility of having a
recombination within the current disease locus that can be used to redefine the boundaries
and narrow the disease locus. This will provide valuable focus to the search for the genetic
cause of disease as there are a large number of candidate genes and variants still located
within the current disease locus.
In the current age of genetic research, it is important for us to increase our venues for
data sharing. Sharing and comparing the results seen in multiple genetic laboratories can
help advance our research. Other labs might have candidate variants that overlap with one
or more from the list I am struggling to narrow down. Seeing a variant shared among more
than one adRP family would provide the evidence necessary to strengthen the pathogenic
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potential of a candidate variant. Data sharing with multiple RP researchers around the
country has already been initiated for this family.
In conclusion, I have identified a novel adRP locus on chromosome 19q that is 7.5
Mb in size and contains the disease-causing gene for the RFS132 family. I have also
identified 63 rare variants located throughout the disease locus that segregate with disease in
this family. Each of these variants remains a potential candidate for the disease-causing
mutation. Use of the valuable genetic information that I have produced in this study will
allow for the identification of this family’s disease-causing gene and mutation in the near
future.
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Appendix A. Retinal Disease Genes Included in Capture Panel for Targeted
Capture NGS. These are the 163 reported retinal disease genes that had been
reported in RetNet at the time of capture panel design. [7, 22]
A6NGG8
ABCA4
ABCC6
ADAM9
AHI1
AIPL1
ALMS1
ARL6
ARMS2
ATXN7
BBS1
BBS10
BBS12
BBS2
BBS4
BBS5
BBS7
BBS9
BEST1
C2
C3
CA4
CABP4
CACNA1F
CACNA2D4
CC2D2A
CDH23
CDH3
CDHR1
CEP290
CERKL
CFB
CFH
CHM
CLN3
CLRN1
CNGA1
CNGA3
CNGB1
CNGB3
CNNM4

Genes in Capture Panel
COL11A1
MYO7A
COL2A1
NDP
COL9A1
NPHP1
CRB1
NPHP3
CRX
NPHP4
CYP4V2
NR2E3
DFNB31
NRL
DMD
NYX
EFEMP1
OAT
ELOVL4
OFD1
ERCC6
OPA1
EYS
OPA3
FBLN5
OPN1LW
FSCN2
OPN1MW
FZD4
OPN1SW
GNAT1
OTX2
GNAT2
PANK2
GPR98
PAX2
GRK1
PCDH15
GRM6
PDE6A
GUCA1A
PDE6B
GUCA1B
PDE6C
GUCY2D
PDZD7
HMCN1
PEX1
HTRA1
PEX2
IDH3B
PEX7
IMPDH1
PGK1
INPP5E
PHYH
INVS
PITPNM3
IQCB1
PRCD
JAG1
PROM1
KCNJ13
PRPF3
KCNV2
PRPF31
KLHL7
PRPF8
LCA5
PRPH2
LRAT
RAX2
LRP5
RB1
MERTK
RBP3
MFRP
RBP4
MKKS
RD3
MTTP
RDH12
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RDH5
RGR
RGS9
RGS9BP
RHO
RIMS1
RLBP1
ROM1
RP1
RP2
RP9
RPE65
RPGR
RPGRIP1
RPGRIP1L
RS1
SAG
SEMA4A
SNRNP200
SPATA7
TEAD1
TIMM8A
TIMP3
TLR3
TLR4
TMEM126A
TOPORS
TREX1
TRIM32
TRPM1
TSPAN12
TTC8
TTPA
TULP1
UNC119
USH1C
USH1G
USH2A
VCAN
WFS1

Appendix B. Chromosome 19 STR marker primer sequences. Only primer sequences for STR markers run on chromosome 19
were included because all other chromosomal regions were effectively ruled-out as potential regions linked to disease in this
family. The information about these primers contained in this appendix will be useful in continuing the search for this family's
disease-causing gene as new family members enrolled in the study will have to be genotyped with these markers to determine if
they have the affected haplotype.
Marker

Forward primer

Reverse primer

Size

Location

D19S220
D19S420
D19S900
D19S538
D19S903
D19S918
D19S908
D19S219
DM
D19S412
D19S606
D19S902
D19S904
D19S907
D19S553

ATGTTCAGAAAGGCCATGTCATTTG
CTGGGGCAGGAGCACT
CCTAATAATCAGTCACTGTCTGG
CACAACACTGTTCATTTGTC
ACCGCACTCCACCCTG
AAAGGCTTGATTACCCCCGA
GTAAGCCAAGATCACTCCCC
GTGAGCCAAGATTGTGCC
CTTCCCAGGCCTGCAGTTTGCCCATC
TGAGCGACAGAATGAGACT
AGGGCTGGGACCTCAC
CCATCCTAATGAGGGCAA
ACAAGAATTGCTTGAACCTGG
GTGTCCAATCAACAGACCA
CATGCCTCTAGTCCCAGCT

TCCCTAACGGATACACAGCAACAC
GCTTACCAAACCTAAAGGATGTC
TTACATGATGCTGGGAACAC
TTTCAGTAGAATTTCAGGCC
TCCTCCTGTGAGATCCTCG
GATTACAGGCGTGAGCACCG
GCCAGGCACTGTTCTGAATA
GACTATTTCTGAGACAGATTCCCA
GAACGGGGCTCGAAGGGTCCTTGTAGC
ACATCTTACTGAATGCTTGC
CCAACACACTGTCTGCCTT
GCACCAGTGACTGCCTGT
GCTCCATTTCGGAGATGTTA
CTGCACTCCAGCAGAAAT
GACAAATGCCAGAAAGCCTG

265-283 bps
251-267 bps
141-177 bps
143-181 bps
132-166 bps
140-182 bps
200-232 bps
160-190 bps
72-129 bps
89-113 bps
172-190 bps
199-217 bps
210-224 bps
213-223 bps
362-479 bps

38,431,551 bp
43,808,760 bp
44,167,258 bp
44,405,515 bp
45,045,901 bp
45,514,778 bp
45,870,527 bp
45,993,577 bp
46,273,386 bp
47,010,944 bp
47,973,563 bp
48,332,028 bp
50,776,794 bp
51,061,251 bp
51,549,504 bp
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